Navigation Links
Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
Date:12/17/2009

Therapure Biopharma to perform fill/finish of nimotuzumab

(PRWEB) December 17, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. and David Allan, Chairman and CEO of YM BioSciences Inc. today announced the signing of an agreement under which Therapure Biopharma will provide aseptic fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM’s majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM). Under the terms of the agreement, Therapure will formulate and fill nimotuzumab into sterile vials in their aseptic GMP certified and Health Canada licensed fill suite in Mississauga, Canada. The facility is built to FDA, EMEA, MHRA and Health Canada standards. The final product will be utilized by YM BioSciences and its licensees, Daiichi Sankyo in Japan, Kuhnil in South Korea, and Oncoscience AG in Europe for all activities and by Innogene Kalbiotech, YM’s licensee in Southeast Asia, for global clinical trials.

Nimotuzumab is a humanized monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), the well-validated oncology target. Nimotuzumab is currently being evaluated in 32 clinical studies worldwide in numerous indications, including multiple stages of non-small cell lung cancer, pediatric and adult glioma, esophageal cancer, pancreatic cancer, gastric cancer and head & neck cancer. Three Phase III trials and eight Phase II trials of those 32 are being conducted between YM and its four licensees. Nimotuzumab has been approved for marketing in 23 countries including Argentina, Brazil, China, India, Indonesia and, most recently, Mexico. In 2009, worldwide revenues for EGFR-targeting monoclonal antibodies are expected to approximate $2 billion.

“We have been very pleased with the performance of nimotuzumab during our on-going clinical
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
2. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
3. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
4. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
5. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
6. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
7. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
8. aTyr Pharma to Present at Japan Biopharma Partnering Conference
9. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
10. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
11. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge ... gears towards the goal for a better future for ... in smaller groups will be held after the conference ... Entrepreneurship, Healthcare, Social and Volunteerism, Women and Youth Empowerment, ... , Young adults aged between 18-30 years that ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to ... thinking. “The #1 block was lack of time ... Haman, who created the Thinkubator Innovation Studio in Chicago. ... they did not have enough time for innovative thinking ... innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops address ...
(Date:2/28/2015)... Morristown, NJ (PRWEB) February 28, 2015 ... Month—is a good time to remind ourselves and ... be ignored, say Atlantic NeuroSurgical Specialists (ANS). , ... (TBI), which account for 75% of TBIs. There ... word concussion may sound benign, but it is ...
(Date:2/28/2015)... CA (PRWEB) February 28, 2015 A ... a promising new gene therapy procedure for the treatment ... blindness in patients. Authored by Dr. Robert ... and published in the Lancet Medical Journal on January ... from choroideremia, a rare genetic disorder that mostly affects ...
(Date:2/28/2015)... National Sales Solutions , ... and supply chain management for consumer packaged goods ... its award winning solutions for thinning-damaged hair to ... specifically created to combat thinning-damaged hair. Known ... to marrying science with nature to create the ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... , SAN DIEGO and BANGALORE, India, ... ) and Biocon, Limited (NSE: BIOCON) announced today that they ... and manufacture a novel peptide therapeutic for the potential treatment ... therapeutic potential of the compound and share development costs. Research ...
... The Gerontological Society of America (GSA) invites all ... the country,s largest interdisciplinary conference in the field of ... Media representatives may register free of charge. An estimated ... the Hilton Atlanta and Atlanta Marriott Marquis ...
... , FALL RIVER, Mass., Sept. 10 ... hired two new experienced professionals to lead significant areas of ... Millstone September 1(st), will serve as Vice President of Technical ... the Memphis, TN, processing and distribution center. He joined ...
... , Gastroenterologists Applaud President,s Call for Coverage ... Gastrointestinal specialists from the American College of Gastroenterology applaud ... breast cancer exams and colonoscopy. In his health care ... President argued that "there,s no reason we shouldn,t be catching ...
... , , BOSTON, Sept. ... plans will soon enjoy a rollback of benchmark prices of ... Appeals Court last week affirmed the approval of a settlement ... a division of Wolters Kluwer Health, Inc. , , ...
... , , , ... products has long been associated with a healthy lifestyle, a new ... Nutrition provides further evidence that grapes and grape products may ... responses. The vast array of naturally occurring plant chemicals in grapes ...
Cached Medicine News:Health News:Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 2Health News:Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 3Health News:Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 4Health News:An invitation to the nation's premier aging conference 2Health News:Millstone Medical Outsourcing Enhances Company Leadership with Two New Hires 2Health News:Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 2Health News:Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 3Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 2Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 3Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 4Health News:Grapes and Grape Products Show Exciting Potential in Optimizing Health 2Health News:Grapes and Grape Products Show Exciting Potential in Optimizing Health 3
(Date:2/27/2015)... SHANGHAI , Feb. 27, 2015 WuXi ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... breakthrough therapy designation from the U.S. FDA for ibalizumab ... therapy if it is intended, alone or in combination ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... the Barclays 2015 Annual Healthcare Conference on March 10 ... Dan Brennan , executive vice president and chief ... Investor Relations, will participate in a 25-minute question and ... at approximately 1:05 p.m. ET. Following a 5-minute break, ...
Breaking Medicine Technology:WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... May 24, 2007 - Generex ... Dr. Douglas Powell, Director,of Immunobiology ... subsidiary,has presented Antigen's vaccine development ... London, UK. The international meeting,"Developing ...
... 2007 /PRNewswire/ -- With enormous,investments and the ... firms need to develop effective strategies for,communicating ... communication planning and execution will gain a ... research and consulting firm Best Practices, LLC,successful ...
Cached Medicine Technology:Generex Biotechnology Vaccine Strategy Presented at International,Conference in London 2Generex Biotechnology Vaccine Strategy Presented at International,Conference in London 3Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
... scotopic sensitivity (threshold) testing provides clinically ... of ophthalmic conditions. Dark adaptometry is ... of retinal degenerations, senile miosis, high ... blinding conditions, while whole-field scotopic sensitivity ...
... Inc.s EPIC-4000 offers fast and easy ERG, ... compact, modular package. It provides ERG stimulus ... the International Standard for the Clinical Electrophysiology ... including the pattern ERG, allow a variety ...
... 3 will enable eye care professionals to ... improved ultrasound technology. The PACHETT 3 uses ... used in all the DGH pachymeters used ... Model 555 PACHETTE 3 is capable of ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: